טוען...
Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) is considered to be a hepatic manifestation of metabolic syndrome, and its incidence is rapidly increasing worldwide. It is currently the most common chronic liver disease. NASH can progress to liver cirrhosis and hepatocel...
שמור ב:
| הוצא לאור ב: | World J Gastroenterol |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Baishideng Publishing Group Inc
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4385525/ https://ncbi.nlm.nih.gov/pubmed/25852263 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v21.i13.3777 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|